Article Text

Download PDFPDF
Authors' response: generic medications in ophthalmology
  1. Alan John Connor,
  2. Scott Fraser
  1. Sunderland Eye Infirmary, Sunderland, Tyne and Wear, UK
  1. Correspondence to Alan John Connor, Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, Tyne and Wear SR2 9HP, UK; dralanconnor{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read the article on ‘Generic medications in ophthalmology’ by Zore et al 1 with great interest. The authors comprehensively describe the regulations that ensure ‘equivalence’ of generic products with branded versions. One aspect of this in ophthalmology, which is overlooked, is the issue of medication compliance with generic eye drops. In order to gain an insight into this, in our own patient population, we conceived an audit looking at generic latanoprost.

Latanoprost was the first prostaglandin analogue to be licensed for the treatment of primary open angle glaucoma and ocular hypertension. In 2012, the patent to …

View Full Text


  • Competing interests None.

  • Contributors AJC and SF contributed to the conception and design, analysis and interpretation of data, drafting the article and final approval of the version to be published.

  • Ethics approval Audit department, City Hospitals Sunderland.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • PostScript
    Alon Harris Brent Siesky Ingrida Januleviciene Leslie Abrams Tobe Matt Zore Annahita Amireskandari Noa Geffen Barbara Wirostko